NEW YORK – Prescribing software developer GenXys Health Care Systems announced on Tuesday that it is partnering with population genomics firm Helix to provide a clinical decision support solution for Helix's platform.
The Vancouver, British Columbia-based company, which currently offers prescription prescribing software solutions with the goal of reducing inappropriate prescribing, said in a statement that its platform will serve as an "interpretation engine" for genetic test results via integration with Helix's clinical platform.
The GenXys platform will be incorporated into the electronic medical record systems of Helix's health system partners, and both companies will provide a multi-factorial population-health focused pharmacogenomic solution, GenXys said. It intends to combine genetic information with applicable results for clinicians at the point of care, the firm added.
"This partnership will benefit Helix [health system] customers as they leverage Helix's 'Sequence Once, Query Often' model; the pharmacogenomics query will have the ability to provide actionable insights every time a prescription is required throughout their patients' lives," GenXys CEO Karl Pringle said in a statement.
San Mateo, California-based Helix's population genomics platform, the Helix Laboratory Platform, was the first whole-exome sequencing platform to receive de novo authorization from the US Food and Drug Administration earlier this year. It detects single nucleotide variants and small insertions and deletions in human genomic DNA extracted from saliva samples.
In June, the company closed a $50 million Series C financing round with plans to use the money to accelerate use of its platform across health systems, life sciences companies, and insurers.